Publications by authors named "Sarah A Kaunfer"
Article Synopsis
- High-dose methotrexate (MTX) can lead to serious complications like acute kidney injury (AKI), neutropenia, and liver damage, but glucarpidase, an enzyme that breaks down MTX, shows potential benefits.
- In a study of 708 patients with MTX-AKI across 28 cancer centers, those receiving glucarpidase had a significantly higher chance of kidney recovery and faster recovery times compared to those who did not receive the treatment.
- Additionally, glucarpidase treatment was associated with lower rates of severe neutropenia and liver enzyme elevation, but there was no notable difference in mortality rates between the two groups.
Objective: To develop and externally validate a prediction model for severe cisplatin associated acute kidney injury (CP-AKI).
Design: Multicenter cohort study.
Setting: Six geographically diverse major academic cancer centers across the US.